

May 15, 2026

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1,
Block- G, Bandra – Kurla Complex,
Bandra (East), Mumbai – 400051
Symbol: AAKAAR

Dear Sir/ Madam,

Ref.: **Outcome of the Board Meeting in accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.**

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') as amended, and other applicable provisions, the Board of Directors of the Company ('the Board'), at its Meeting held today, i.e., Friday, May 15, 2026, has inter alia considered and approved:

1. Financial Results

Approved the Audited Financial Results of the Company, for the year ended on March 31, 2026, as reviewed by the Audit Committee. In this regard, please find enclosed Audited Financial Results and Segment wise Results of the Company for the year ended March 31, 2026 along with Statement of Assets and Liabilities and Cash flow statement, subject to adoption by shareholders at the ensuing Annual General Meeting. The said results are also being uploaded on the website of the company viz. www.akaarmedical.in

2. M/s. C.B. Mehta & Associates Chartered Accountants, Statutory Auditors of Company, have issued the Audit Report on the above-mentioned results with unmodified opinion in terms of Regulation 33(3)(d) of the SEBI Listing Regulations.
3. Based on the recommendation of the Nomination and Remuneration Committee, approved the re-appointment of Mr. Dilip Ramesh Meswani, Non-Independent Director, who is liable to retire by rotation, subject to approval of Shareholders and Securities and Exchange Board of India.

Accordingly, the requisite disclosure in terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read SEBI Master Circular dated January 30, 2026, bearing reference no. HO/49/14/14(7)2025-CFD-POD2/I/376/2026 is enclosed.

The Meeting of the Board of Directors of the Company commenced at 3.35 P.M. IST and concluded at 4.00 P.M. IST

You are requested to disseminate the above information on your website.

Yours truly,
For **Aakaar Medical Technologies Ltd.**

Anoopkumar V. Pillai
Company Secretary & Compliance Officer

Encl: As above.

Annexure A

Details	Particulars
Name of Director	Mr. Dilip Ramesh Meswani
DIN	06540985
Reason for change	Re-appointment of Director retiring by rotation under the provisions of the Companies Act, 2013
Date of re-appointment and term of re-appointment	May 15 th , 2026
Brief Profile	Mr. Dilip Ramesh Meswani is the Managing Director and also one of the Promoters of our Company. He has been associated with the Company since June 20, 2013, as a Director and Promoter of our Company. He possesses more than 24 years of experience in the fields of Medical Aesthetics and has been instrumental in the excellent growth of the company.
Qualification	He has completed his degree of Bachelor of Science from University of Bombay. He has also completed his Post Graduate Diploma in Medical Electronics from Shri Bhagubhai Mafatlal Polytechnic, Mumbai.
Disclosure of Relations between Directors	Spouse of Mrs. Bindi Meswani
Other details	Mr. Dilip Meswani is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.



AAKAAR MEDICAL TECHNOLOGIES LIMITED

(Formerly known as AAKAAR MEDICAL TECHNOLOGIES PRIVATE LIMITED)

Registered Address: A-801, Heritage Plaza, Teli Gali, Cross Road, Andheri (E), Mumbai 400069

CIN : L74900MH2013PLC244717

Statement of Audited Financial Results for the half year and year ended March 31, 2026

(Amount in lacs except EPS)

Particulars	For the half year ended			For the year ended	
	Mar 31, 2026 (Audited)	Sept 30, 2025 (Unaudited)	Mar 31, 2025 (Audited)	Mar 31, 2026 (Audited)	Mar 31, 2025 (Audited)
I Revenue from operations	4,163.92	2,532.49	3,387.86	6,696.41	6,158.20
II Other income	63.48	29.71	11.02	80.44	17.79
III Total income (I + II)	4,227.39	2,562.21	3,398.88	6,776.85	6,176.00
IV Expenses:					
Cost of material consumed	238.17	202.82	190.39	440.98	353.00
Purchases of Stock-in-Trade	1,501.79	1,397.35	1,094.90	2,899.13	2,306.90
Changes in inventories of Stock-in-Trade and finished goods	(63.90)	(455.71)	36.57	(519.61)	(37.41)
Employee benefit expense	674.68	726.40	645.21	1,401.08	1,290.20
Finance costs	75.54	104.07	90.69	179.61	170.90
Depreciation and amortisation expenses	7.92	4.91	6.66	12.83	12.41
Other expenses	771.69	684.70	586.27	1,443.64	1,268.50
Total expenses	3,205.88	2,664.54	2,650.67	5,857.67	5,364.70
V Profit before tax (III-IV)	1,021.51	(102.33)	748.20	919.18	811.30
VI Prior period items	-	-	-	-	-
VII Tax expense:					
Current tax expense for the year	262.63	(18.54)	174.66	244.08	192.60
Short/ (excess) provision	18.71	-	19.65	18.71	19.60
Deferred tax expenses	(1.99)	(5.38)	(2.89)	(7.38)	(4.10)
	279.35	(23.93)	191.41	255.42	208.00
VIII Profit/ (Loss) for the period (V-VI-VII)	742.16	(78.41)	556.79	663.76	603.20
IX Earnings per equity share (EPS):					
Basic	5.24	(0.63)	5.35	4.99	6.10
Diluted	5.24	(0.63)	5.35	4.99	6.10

See accompanying Notes to Financial Results

For and on behalf of
Aakaar Medical Technologies Limited



Dilip Meswar

Dilip Meswar
Founder & Managing Director
DIN 0654098

Place: Mumbai
Date: 15th May, 2026



AAKAAR MEDICAL TECHNOLOGIES LIMITED

(Formerly known as AAKAAR MEDICAL TECHNOLOGIES PRIVATE LIMITED)

Registered Address: A-801, Heritage Plaza, Teli Gali, Cross Road, Andheri (E), Mumbai 400069

CIN : L74900MH2013PLC244717

Statement of Assets and Liabilities as at March 31, 2026

(Amount in Lacs)

Particulars	For the year ended	
	As at Mar 31, 2026 (Audited)	As at Mar 31, 2025 (Audited)
EQUITY AND LIABILITIES		
1 Equity		
Shareholders' funds		
(a) Share capital	1,417.28	1,042.24
(b) Reserves and surplus	4,037.78	1,283.58
	5,455.06	2,325.82
2 Liabilities		
Non-current liabilities		
(a) Long-term provisions	98.29	94.51
	98.29	94.51
Current liabilities		
(a) Short-term borrowings	1,853.43	2,273.83
(b) Trade payables		
Total outstanding dues of micro enterprises and small enterprises; and	70.06	3.11
Total outstanding dues of creditors other than micro enterprises and small enterprises	118.40	348.05
(c) Other current liabilities	204.32	284.10
(d) Short-term provisions	142.09	86.55
	2,388.30	2,995.64
	7,941.66	5,415.97
ASSETS		
1 Non-current assets		
(a) Property, Plant and Equipment and Intangible assets		
i. Property, Plant and Equipments	16.94	22.81
ii. Intangible assets	12.06	0.94
iii. Intangible assets under development	39.74	-
(b) Deferred tax assets (Net)	46.97	39.59
(c) Long term loans and advances	31.21	39.54
(d) Other non-current assets	133.53	129.54
	280.45	232.42
2 Current assets		
(a) Inventories	1,975.04	1,455.42
(b) Trade receivables	3,722.52	2,800.45
(c) Cash and bank balance	1,624.33	555.08
(d) Short term loans and advances	3.34	13.98
(d) Other current assets	335.98	358.62
	7,661.21	5,183.55
	7,941.66	5,415.97

See accompanying Notes to Financial Results

For and on behalf of
Aakaar Medical Technologies Limited



Dilip Meswani
Founder & Managing Director
DIN 06540985

Place: Mumbai
Date: 15th May, 2026



AAKAAR MEDICAL TECHNOLOGIES LIMITED

(Formerly known as AAKAAR MEDICAL TECHNOLOGIES PRIVATE LIMITED)

Registered Address: A-801, Heritage Plaza, Teli Gali, Cross Road, Andheri (E), Mumbai 400069

CIN : L74900MH2013PLC244717

Statement of Cash Flows for the year ended March 31, 2026

(Amount in Lacs)

Particulars	For the year ended	
	Mar 31, 2026 (Audited)	Mar 31, 2025 (Audited)
A. Cash flow from operating activities		
Net Profit / (Loss) before tax	919.18	811.37
Adjustments for:		
Depreciation and amortisation	12.83	12.48
Interest income	(77.97)	(1.31)
Balance written back	(0.01)	(1.83)
Share based payment expenses	-	1.60
Sundry balances written off	30.43	3.23
Foreign exchange gain/ loss	(1.51)	(13.47)
Finance costs	165.45	157.71
Operating profit / (loss) before changes in operating assets	1,048.40	969.78
Changes in Operating Assets:		
Adjustments for (increase) / decrease in operating assets:		
(Increase)/ Decreases in trade receivables	(952.50)	(1,177.43)
(Increase)/ Decreases in inventories	(519.61)	(37.48)
(Increase)/ Decreases in other assets	13.07	(245.31)
(Increase)/ Decreases in loans and advances	7.39	(41.95)
Increase/ (Decrease) in trade payables	(161.18)	184.77
Increase/ (Decrease) in short term provisions	29.31	2.75
Increase/ (Decrease) in long term provisions	3.78	11.48
Increase/ (Decrease) in other current liabilities	(79.78)	(8.46)
Cash generated from operations	(611.12)	(341.85)
Net income tax (paid) / refunds received	(225.01)	(198.77)
Net cash flow used in operating activities	(836.13)	(540.62)
B. Cash flow from investing activities		
Purchase of fixed asset	(57.82)	(8.39)
Interest received	57.76	0.46
Term deposits	4.93	2.53
Net cash flow used in investing activities	4.87	(5.40)
C. Cash flow from financing activities		
Proceeds from cash credit/ overdraft facility	(165.79)	1,022.76
Net Increase / (Decrease) of borrowings	(254.60)	(254.60)
Proceeds from issue of shares	2,700.29	525.67
Share issue expenses	(234.81)	(65.11)
Finance cost	(165.45)	(157.71)
Net cash flow generated from financing activities	1,879.64	1,071.01
Net decrease in Cash and cash equivalents (A+B+C)	1,048.38	524.99
Cash and cash equivalents at the beginning of the year	554.64	29.65
Cash and cash equivalents at the end of the year	1,603.03	554.64
Components of cash and cash equivalents		
Balance with banks and cash on hand	1,603.03	554.64
	1,603.03	554.64

See accompanying Notes to Financial Results

For and on behalf of
Aakaar Medical Technologies Limited



D. Meswani

Dilip Meswani
Founder & Managing Director
DIN 06540985

Place: Mumbai
Date: 15th May, 2026

Notes to Financial Results

- The Financial Results are prepared in accordance with the Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounting) Rules, 2014 (as amended) and other recognized accounting practices and policies as applicable.
- The above results were reviewed by Audit Committee and were approved and taken on record by the Board of Directors in their meeting held on 15th May, 2026.
- Basic and Diluted EPS have been computed in accordance with Accounting Standard on Earning Per Share (EPS) AS-20.
- The Company operates through two segments viz. manufacturing and distribution of Aesthetic Devices & Device consumables and Aesthetic Products. Details of the same are as per the annexure attached.
- The figures for the half year ended March 2026 & March 2025 are the balancing figures between the audited figures of full financial year and the figures upto half year ended September 2025 and September 2024 respectively.
- The Company has issued and allotted 37,50,400 Equity Shares of face value of Rs 10 each at the price of Rs 72 each (including Rs 62 Security Premium) for total consideration of Rs. 2,700.29 Lakhs through SME IPO (Initial Public Offer) on National Stock Exchange of India (NSE). Pursuant to the allotment of Equity shares, the paid-up Equity Share capital of the company stands increased at Rs. 1417.28 Lakhs.
- The details of utilization of IPO Proceeds of Rs. 2700.29 lakhs are as follows:

Particulars	Proceeds	Utilisation upto 31 st March, 2026	Unutilised upto 31 st March, 2026*
Working Capital	2,035.00	935.00	1,100.00
General Corporate Purpose**	329.00	0.63	328.37
Issue expenses paid with GST	336.29	336.29	-
Total	2,700.29	1,271.92	1,428.37

(Rs. in lacs)

(*The above unutilised amount as at 31st March 2026, has been kept in a fixed deposit with a scheduled bank.)

(**The GCP Component 0.63 includes issues expenses 0.63 Lacs with GST on and above estimated issue expenses of



CIN No.: L74900MH2013PLC244717

Aakaar Medical Technologies Limited
(formerly: Aakaar Medical Technologies Pvt.Ltd.)
A-801, Heritage Plaza, Teli Gali Cross Road
Andheri (East), Mumbai – 400 069 INDIA
Mob: + 91 9820317468
E-mail: info@akaarmedical.in
www.akaarmedical.in
GST No: 27AALCA7587Q1ZK

Rs. 336.29 lacs paid - with GST.)

8. Previous year figures have been regrouped / rearranged wherever necessary to correspond with the current year's classification / disclosures.

For Aakaar Medical Technologies Limited

Dilip Meswani
Managing Director
DIN – 06540985



Place: Mumbai
Dated: 15th May, 2026



CIN No.: L74900MH2013PLC244717

Aakaar Medical Technologies Limited
 (formerly: Aakaar Medical Technologies Pvt.Ltd.)
 A-801, Heritage Plaza, Teli Gali Cross Road
 Andheri (East), Mumbai – 400 069 INDIA
 Mob: + 91 9820317468
 E-mail: info@aakaarmedical.in
 www.aakaarmedical.in
 GST No: 27AALCA7587Q1ZK

Annexure

Sr No.	Particulars	For the half year ended			For the year ended	
		Mar 31, 2026 (Audited)	Sept 30, 2025 (Unaudited)	Mar 31, 2025 (Audited)	Mar 31, 2026 (Audited)	Mar 31, 2025 (Audited)
A	Segment Revenue					
	Aesthetic Devices & Device consumables	400.66	335.00	469.72	735.66	854.72
	Aesthetic Products	3,763.26	2,197.49	2,918.13	5,960.75	5,303.56
	Total Revenue	4,163.92	2532.49	3387.85	6,696.41	6,158.28
B	Result					
	Segment Profit					
	Aesthetic Devices & Device consumables	268.32	167.5	277.46	435.82	469.96
	Aesthetic Products	1,407.73	976.96	1044.41	2,384.69	2,152.53
	Segment Operating Profit	2,487.87	1388.03	2065.98	3,875.90	3,535.79
	Reconciliation of segment operating profit to operating profit					
	Unallocated:					
	Employee Benefit Expense	674.68	726.4	645.22	1,401.08	1,290.26
	Other Expense	766.87	689.6	592.92	1,456.47	1,281.02
	Other miscellaneous expenses net of income	(50.73)	(29.71)	(11.02)	(80.44)	(17.79)
	Operating Profit	1,097.05	1.74	838.86	1,098.79	982.3
	Finance Costs	75.54	104.07	90.68	179.61	170.94
	Profit before tax	1021.51	-102.33	748.18	919.18	811.36
C	Segment Assets					
	Aesthetic Devices & Device consumables	1,035.23	122.68	183.21	1,035.23	183.21
	Aesthetic Products	4,662.33	2526.72	2617.24	4,662.33	2,617.24
	Unallocated Corporate Assets	2,244.11	4467.03	2615.52	2,244.11	2,615.52
	Total Assets	7,941.67	7,116.43	5,415.97	7,941.67	5,415.97
D	Segment Liabilities					
	Unallocated Corporate liabilities	2,486.60	2402.51	3090.16	2,486.60	3,090.16
	Total Liabilities	2,486.60	2402.51	3090.16	2,486.60	3,090.16



Independent Auditor's Report on Half Yearly and Year to date Financial Results of **Aakaar Medical Technologies Limited** Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To

The Board of Directors of Aakaar Medical Technologies Limited
(formerly known as Aakaar Medical Technologies Private Limited)

Report on the Audit of the Financial Results

Opinion

We have audited the accompanying financial statements of **Aakaar Medical Technologies Limited** ("the Company") for half Year ended 31st March, 2026 and year to date results for the period from 1st April 2025 to 31st March 2026 (the "Statement"), attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations")

In our opinion and to the best of our information and according to the explanations given to us, the statements:

- i. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard;
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India, of the Net profit and other financial information of the Company as at March 31, 2026 and its profit, and its cash flows for the year ended on that date.



Basis for Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing (“SA”s) specified under section 143(10) of the Companies Act 2013 (“The Act”). Our responsibilities under those Standards are further described in the Auditor’s Responsibilities for the Audit of the Annual financial result section of our report.

We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (“ICAI”) together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI’s Code of Ethics.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the financial results.

Responsibilities of Management and Those Charged with Governance for the Financial Results

These financial results have been prepared based on the annual financial statements. The Company’s management and Board of Directors are responsible for the preparation and presentation of these annual financial results that give a true and fair view of the net profit and Other financial Information in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.



In preparing the annual financial results, the management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such control.



CHARTERED ACCOUNTANTS



- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in:

- (i) planning the scope of our audit work and in evaluating the results of our work; and
- (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Other Matters

The Statement includes the results for the half year ended 31st March 2026 being the balancing figures between the audited figures in respect of the full financial year ended 31st March 2026 and the published unaudited year to date figures up to the period ended 30th September 2025 which were subjected to a limited review by us, as required under the Listing Regulations.

Our report is not modified in respect of this matter

For C B Mehta & Associates

Chartered Accountants

FRN: 124978W

C.B. Mehta

Proprietor

MRN: 116543

Place: Mumbai

Dated: 15th May, 2026

UDIN: 26116543JQKJJB8085



Declaration by Statutory Auditors Regarding Unmodified Opinion

To

The Board of Directors
Aakaar Medical Technologies Ltd.

A-801, Heritage Plaza
Teli Gali Cross Road
Andheri East
Mumbai-400069.

Declaration Regarding Unmodified Opinion on Annual Audited Financial Results for the Financial Year Ended 31 March 2026.

We, the Statutory Auditors of Aakaar Medical Technologies Ltd. ("the Company"), have audited the standalone financial statements of the Company for the financial year ended 31 March 2026.

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, and the relevant circulars issued thereunder, we hereby confirm and declare that our Audit Report on the annual audited financial results / financial statements of the Company for the financial year ended 31 March 2026 carries an **unmodified opinion**.

For C B Mehta & Associates
Chartered Accountants
Firm Registration No: 124978W



Chirag B Mehta
Proprietor
Membership No: 116543

Place: Mumbai
Date: 15th May, 2026

